Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease

Jee Hyun Kim; Ji Won Kim

doi:10.4166/kjg.2017.70.4.162

Journal List > Korean J Gastroenterol > v.70(4) > 1007692

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim and Kim: Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease

Review Article

Korean J Gastroenterol 2017;70(4):162-168.

Published online: 4 October 2017

DOI: https://doi.org/10.4166/kjg.2017.70.4.162

Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease

Jee Hyun Kim^1,², Ji Won Kim^1,²

¹Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

²Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea

Correspondence to: Ji Won Kim, Division of Gastroenterology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Korea. Tel: + 82-2-870-2221, Fax: + 82-2-870-3863, E-mail: kjwjor@snu.ac.kr

Received 6 September 2017 Revised 25 September 2017 Accepted 17 October 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Immunosuppressive agents and biological agents are widely used for therapy in patients with inflammatory bowel disease (IBD). However, these therapies may be associated with an increased risk of malignancy. There is evidence that exposure of the therapeutic agents such as thiopurine and anti-tumor necrosis factor for IBD is associated with an increased risk of lymphoproliferative disorders, skin cancers, or uterine cervical cancers. This article reviews the malignancies associated with the use of immunosuppressive agents and biological agents in IBD.

Keywords: Inflammatory bowel disease, Malignancy, Azathioprine, 6-Mercaptopurine, Tumor necrosis factor-alpha

References

1. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016; 14:111–119.

2. Beigel F, Steinborn A, Schnitzler F, et al. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti‐TNF alpha antibodies. Pharmacoepidemiol Drug Saf. 2014; 23:735–744.

3. Beaugerie L. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? Gut. 2012; 61:476–483.

4. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a metaanalysis. Gut. 2001; 48:526–535.

5. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006; 130:1030–1038.

6. Zhiqin W, Palaniappan S, Raja Ali RA. Inflammatory bowel disease-related colorectal cancer in the Asia-Pacific region: past, present, and future. Intest Res. 2014; 12:194–204.

7. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer: a population-based study. N Engl J Med. 1990; 323:1228–1233.

8. Söderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009; 136:1561–1567. quiz 1818–1819.

9. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001; 91:854–862.

10. Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006; 130:1039–1046.

11. Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012; 143:375–381. e1;quiz e13–14.

12. Kim BJ, Yang SK, Kim JS, et al. Trends of ulcerative colitis‐associated colorectal cancer in Korea: a KASID study. J Gastroenterol Hepatol. 2009; 24:667–671.

13. Rhodes JM, Campbell BJ. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Ned. 2002; 8:10–16.

14. Yeo M, Surh YJ, Hahm KB. Crossroad between inflammation and carcinogenesis in colon. Korean J Med. 2006; 70:130–137.

15. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007; 67:1167–1198.

16. van Schaik FD, van Oijen MG, Smeets HM, van der Heijden GJ, Siersema PD, Oldenburg B. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut. 2012; 61:235–240.

17. Gong J, Zhu L, Guo Z, et al. Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a metaanalysis. PLoS One. 2013; 8:e81487.

18. Jess T, Lopez A, Andersson M, Beaugerie L, Peyrin-Biroulet L. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a metaanalysis. Clin Gastroenterol Hepatol. 2014; 12:1793–1800.e1.

19. Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013; 145:166–175.e8.

20. Baars JE, Looman CW, Steyerberg EW, et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested casecontrol study. Am J Gastroenterol. 2011; 106:319–328.

21. Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-αantagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014; 311:2406–2413.

22. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009; 9:361–371.

23. Onizawa M, Nagaishi T, Kanai T, et al. Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2009; 296:G850–G859.

24. Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TI. Increased risk of intestinal cancer in Crohn's disease: a metaanalysis of population-based cohort studies. Am J Gastroenterol. 2005; 100:2724–2729.

25. Canavan C, Abrams KR, Mayberry J. Meta‐analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther. 2006; 23:1097–1104.

26. von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum. 2007; 50:839–855.

27. Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014; 12:265–273.e1.

28. Solem CA, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Small intestinal adenocarcinoma in Crohn's disease: a case‐control study. Inflamm Bowel Dis. 2004; 10:32–35.

29. Egan L, D'Inca R, Jess T, et al. Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (II). J Crohns Colitis. 2014; 8:19–30.

30. Kronberger IE, Graziadei IW, Vogel W. Small bowel adenocarcinoma in Crohn's disease: a case report and review of literature. World J Gastroenterol. 2006; 12:1317–1320.

31. Lashner BA. Risk factors for small bowel cancer in Crohn's disease. Dig Dis Sci. 1992; 37:1179–1184.

32. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based casecontrol study. Am J Gastroenterol. 2010; 105:1604–1609.

33. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009; 374:1617–1625.

34. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54:1121–1125.

35. Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007; 41:21–28.

36. Park SK, Ye BD, Lee C, et al. Risk and clinical characteristics of lymphoma in Korean patients with inflammatory bowel diseases: a multicenter study. J Clin Gastroenterol. 2015; 49:e11–e16.

37. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant. 2003; 31:145–155.

38. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002; 122:72–77.

39. Vos A, Bakkal N, Minnee RC, et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis. 2011; 17:1837–1845.

40. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol. 2007; 38:1293–1304.

41. Magro F, Peyrin-Biroulet L, Sokol H, et al. Extraintestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (III). J Crohns Colitis. 2014; 8:31–44.

42. Lichtenstein GR, Feagan BG, Cohen RD. et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™registry. Am J Gastroenterol. 2012; 107:1409–1422.

43. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359:1541–1549.

44. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004; 126:19–31.

45. Ljung T, Karlén P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004; 53:849–853.

46. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: metaanalysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008; 6:644–653.

47. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREATTM registry. Am J Gastroenterol. 2014; 109:212–223.

48. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a metaanalysis. Clin Gastroenterol Hepatol. 2009; 7:874–881.

49. Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011; 106:2146–2153.

50. Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol. 2010; 6:621–631.

51. Luthra P, Peyrin‐Biroulet L, Ford AC. Systematic review and meta‐analysis: opportunistic infections and malignancies during treatment with anti‐integrin antibodies in inflammatory bowel disease. Aliment Pharmacol Ther. 2015; 41:1227–1236.

52. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011; 9:36–41.e1.

53. Kotlyar DS, Blonski W, Diamond RH, Wasik M, Lichtenstein GR. Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. Am J Gastroenterol. 2010; 105:2299–2301.

54. Ochenrider MG, Patterson DJ, Aboulafia DM. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk. 2010; 10:144–148.

55. Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014; 63:1416–1423.

56. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010; 4:28–62.

57. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011; 141:1621–1628. e1–5.

58. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a metaanalysis. Am J Gastroenterol. 2014; 109:163–169.

59. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012; 143:390–399.e1.

60. McKenna MR, Stobaugh DJ, Deepak P. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-αinhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis. 2014; 23:267–271.

61. Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer. 1991; 67:2015–2019.

62. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010; 8:268–274.

63. Ahn SM, Suh SO, Oh YM, et al. A case of pleomorphic liposarcoma in a patient with Crohn's disease taking azathioprine. Korean J Gastroenterol. 2013; 62:248–252.

64. Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and metaanalysis. Clin Gastroenterol Hepatol. 2014; 12:210–218.

65. Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006; 12:6167–6171.

66. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008; 103:631–636.

67. Allegretti JR, Barnes EL, Cameron A. Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A metaanalysis. Inflamm Bowel Dis. 2015; 21:1089–1097.

68. Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested casecontrol study. Gastroenterology. 2009; 136:451–458.

69. Rahier J, Magro F, Abreu C, et al. Second European evidencebased consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014; 8:443–468.

TOOLS

Similar articles